Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 3/20 | 0.37 |
| ▸ | PDE4B | Q07343 | 3/20 | 0.37 |
| ▸ | PDE4C | Q08493 | 3/20 | 0.37 |
| ▸ | PDE4D | Q08499 | 3/20 | 0.37 |
| ▸ | FGFR3 | P22607 | 2/20 | 0.33 |
| ▸ | FGFR4 | P22455 | 2/20 | 0.33 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.33 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | GLA | P06280 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | VEGFA | P15692 | 1/20 | 0.32 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.32 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4408963 | 0.89 | ENPP1 (0.36) | PDE4APDE4BPDE4CPDE4DFGFR3 | |
| SCHEMBL4395425 | 0.89 | ENPP1 (0.36) | PDE4APDE4BPDE4CPDE4DFGFR4 | |
| SCHEMBL4397903 | 0.87 | HMGCR (0.41) | PDE4APDE4BPDE4CPDE4DMEN1 | |
| SCHEMBL4411924 | 0.86 | PDE4A (0.43) | PDE4APDE4BPDE4CPDE4DFGFR3 | |
| SCHEMBL21280364 | 0.86 | PDE4A (0.43) | PDE4APDE4BPDE4CPDE4DGAA | |
| SCHEMBL15725837 | 0.86 | PDE4A (0.35) | PDE4APDE4BPDE4CPDE4DFGFR4 | |
| SCHEMBL4405723 | 0.86 | HMGCR (0.40) | PDE4APDE4BPDE4CPDE4DMEN1 | |
| SCHEMBL18781430 | 0.83 | KDM4E (0.36) | FGFR3GAALMNATP53NPSR1 | |
| SCHEMBL16993164 | 0.81 | GAA (0.33) | FGFR3GAAALDH1A1 | |
| SCHEMBL4404738 | 0.81 | GAA (0.41) | GAALMNATP53NPSR1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2821402-B1 | NITROGEN-CONTAINING AROMATIC HETEROCYCLIC COMPOUND | ASTELLAS PHARMA INC (JP) | 2019-08-21 | — | — | EP | disclosed |
| EP-2821402-B1 | NITROGEN-CONTAINING AROMATIC HETEROCYCLIC COMPOUND | ASTELLAS PHARMA INC (JP) | 2019-08-21 | — | — | EP | disclosed |
| US-20170152232-A1 | NITROGEN-CONTAINING AROMATIC HETEROCYCLIC COMPOUND | ASTELLAS PHARMA INC. (JP) | 2017-06-01 | — | — | US | disclosed |
| US-20170152232-A1 | NITROGEN-CONTAINING AROMATIC HETEROCYCLIC COMPOUND | ASTELLAS PHARMA INC. (JP) | 2017-06-01 | — | — | US | disclosed |
| US-9464077-B2 | Nitrogen-containing aromatic heterocyclic compound | ASTELLAS PHARMA INC. (JP) | 2016-10-11 | — | — | US | disclosed |
| US-9464077-B2 | Nitrogen-containing aromatic heterocyclic compound | ASTELLAS PHARMA INC. (JP) | 2016-10-11 | — | — | US | disclosed |
| EP-2821402-A1 | NITROGEN-CONTAINING AROMATIC HETEROCYCLIC COMPOUND | Astellas Pharma Inc. (JP) | 2015-01-07 | — | — | EP | disclosed |
| EP-2821402-A1 | NITROGEN-CONTAINING AROMATIC HETEROCYCLIC COMPOUND | Astellas Pharma Inc. (JP) | 2015-01-07 | — | — | EP | disclosed |
| US-20140142084-A1 | NITROGEN-CONTAINING AROMATIC HETEROCYCLIC COMPOUND | KOTOBUKI PHARMACEUTICAL CO., LTD. (JP) | 2014-05-22 | — | — | US | disclosed |
| US-20140142084-A1 | NITROGEN-CONTAINING AROMATIC HETEROCYCLIC COMPOUND | KOTOBUKI PHARMACEUTICAL CO., LTD. (JP) | 2014-05-22 | — | — | US | disclosed |
| EP-1549651-B1 | PYRIMIDOPYRIMIDONES AS KINASE INHIBITORS | WARNER LAMBERT CO (US) | 2009-12-23 | — | — | EP | disclosed |
| US-7196090-B2 | Kinase inhibitors | WARNER-LAMBERT COMPANY (US) | 2007-03-27 | — | — | US | disclosed |
| EP-1549651-A1 | KINASE INHIBITORS | Warner-Lambert Company LLC (US) | 2005-07-06 | — | — | EP | disclosed |
| WO-2004011465-A1 | KINASE INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2004-02-05 | — | — | WO | disclosed |
| US-20040019210-A1 | Kinase inhibitors | CHIVIKAS CONNOLLY CLEO J (US) | 2004-01-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140142084-A1 | NITROGEN-CONTAINING AROMATIC HETEROCYCLIC COMPOUND | FGFR3, FGFR1, FGFR2 | PDE4A 4275/4885PDE4B 4222/4885PDE4C 4205/4885 |
| US-20040019210-A1 | Kinase inhibitors | CDK2, CDK1, CDK4 | PDE4A 1438/4885PDE4B 1642/4885PDE4C 1544/4885 |
| US-20170152232-A1 | NITROGEN-CONTAINING AROMATIC HETEROCYCLIC COMPOUND | FGFR3, FGFR1, FGFR2 | PDE4A 4236/4885PDE4B 4160/4885PDE4C 4124/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.